U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417618) titled 'INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)' on Feb. 11.
Brief Summary: Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Study Start Date: Jan. 27
Study Type: OBSERVATIONAL
Condition:
Type 2 Diabetes
Overweight
ASCVD
Intervention:
DRUG: Dulaglutide
Initiation of dulaglutide dispensing claim is used as t...